Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
75 stopped studies mapped to Malignant Thyroid Gland Neoplasm and descendants · 92% state a reason
Over the 75 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | — | terminated | Oct 12, 2022 | Mayo Clinic | Slow accrual; lack of eligible study participants | Enrollment / accrual |
| NCT04040673 | RAman For Thyroid cancER(RAFTER) | — | withdrawn | Aug 1, 2019 | Gloucestershire Hospitals NHS Foundation Trust | Covid19 halted study | COVID-19 / pandemic |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT05591092 | Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular… | — | terminated | Oct 24, 2022 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06465017 | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | N/A | terminated | Jun 18, 2024 | The First Affiliated Hospital of Xiamen University | The study was completed as planned after achieving the target enrollment and completing all… | Enrollment / accrual |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory…(DUTHY) | Phase 2 | terminated | Nov 27, 2018 | Grupo Espanol de Tumores Neuroendocrinos | In compliance with current legislation applicable to Clinical Trials, following the instructions of… | Other (stated, no rule matched) |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT04136912 | 3-D Super Resolution Ultrasound Microvascular Imaging | Phase 2 | terminated | Oct 23, 2019 | UNC Lineberger Comprehensive Cancer Center | Grant ended | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05774535 | Prospective, Observational Study on the Carotid Intima-media Thickness in Patients…(TIROVASC) | — | withdrawn | Mar 17, 2023 | Istituto Auxologico Italiano | No enrollment | Enrollment / accrual |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid… | Phase 1 | terminated | Mar 19, 2018 | AHS Cancer Control Alberta | Lack of Accrual | Enrollment / accrual |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT05003856 | Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule | N/A | terminated | Aug 12, 2021 | M.D. Anderson Cancer Center | Administrativley Complete, 75%\<Participants | Other (stated, no rule matched) |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT05328076 | Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography(ANGIO_PARA) | — | terminated | Apr 14, 2022 | IRCCS San Raffaele | We encountered problems in finding the necessary resources in the Institute | Other (stated, no rule matched) |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | Phase 2 | terminated | Mar 31, 2020 | Vanderbilt-Ingram Cancer Center | Funding ended | Funding |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid… | Phase 1 | withdrawn | Apr 30, 2021 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in… | Phase 2 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Slow/Insufficient accrual | Enrollment / accrual |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT03065218 | 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid… | Phase 4 | terminated | Feb 27, 2017 | Medstar Health Research Institute | Insufficient recruitment | Enrollment / accrual |
| NCT00373711 | Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent… | — | withdrawn | Sep 8, 2006 | Stanford University | Abandoned | Other (stated, no rule matched) |
| NCT04224792 | Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors | N/A | withdrawn | Jan 13, 2020 | Mayo Clinic | Due to pandemic, unable to see patients | COVID-19 / pandemic |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT03139747 | UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients… | Phase 2 | suspended | May 4, 2017 | Thomas Jefferson University | lack of accrual reevaluating feasibility | Enrollment / accrual |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid… | Phase 1 / Phase 2 | terminated | Apr 27, 2017 | Dana-Farber Cancer Institute | Study closed due to slow accrual and lack of efficacy. | Efficacy / futility |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid… | Phase 2 | terminated | Mar 13, 2018 | University of California, San Francisco | Funding | Funding |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid… | N/A | withdrawn | Oct 15, 2012 | Medstar Health Research Institute | not stated | Not stated |
| NCT02946918 | Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy | Phase 4 | terminated | Oct 27, 2016 | University of Texas Southwestern Medical Center | Terminating study as sponsor has sold the drug to another company | Sponsor / business decision |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | Phase 1 / Phase 2 | terminated | Jan 29, 2008 | Daiichi Sankyo | Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated… | Safety / toxicity |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT01265381 | Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study | — | terminated | Dec 23, 2010 | National Cancer Institute (NCI) | This protocol was determined to be not human subjects research. | Other (stated, no rule matched) |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor… | Phase 1 / Phase 2 | withdrawn | Mar 18, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | N/A | terminated | Nov 1, 2013 | Yale University | Lack of patient enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials